5F-CUMYL-PEGACLONE

5F-CUMYL-PEGACLONE (5F-SGT-151, SGT-269) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug, first being identified in Germany in 2017. It acts as a potent full agonist of the CB1 receptor. [1][2] It appears to be more toxic than related compounds such as CUMYL-PEGACLONE, and has been linked to numerous serious adverse reactions, some fatal.[3]

5F-CUMYL-PEGACLONE
Legal status
Legal status
Identifiers
  • 2,5-Dihydro-2-(1-methyl-1-phenylethyl)-5-(5-fluoropentyl)-1H-pyrido[4,3-b]indol-1-one
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC25H27FN2O
Molar mass390.502 g·mol−1
3D model (JSmol)
  • CC(C)(c1ccccc1)N4C=Cc3n(CCCCCF)c2ccccc2c3C4=O
  • InChI=1S/C25H27FN2O/c1-25(2,19-11-5-3-6-12-19)28-18-15-22-23(24(28)29)20-13-7-8-14-21(20)27(22)17-10-4-9-16-26/h3,5-8,11-15,18H,4,9-10,16-17H2,1-2H3
  • Key:SMRRORRDOWXERZ-UHFFFAOYSA-N

See also

References
  1. Mogler L, Halter S, Wilde M, Franz F, Auwärter V (2019). "Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE". Forensic Toxicology. 37 (1): 154–163. doi:10.1007/s11419-018-0447-4. PMC 6315001. PMID 30636984.
  2. Janssens L, Cannaert A, Connolly MJ, Liu H, Stove CP (June 2020). "In vitro activity profiling of Cumyl-PEGACLONE variants at the CB1 receptor: Fluorination versus isomer exploration". Drug Testing and Analysis. 12 (9): 1336–1343. doi:10.1002/dta.2870. hdl:1854/LU-8687072. PMID 32490586. S2CID 219285656.
  3. Giorgetti A, Mogler L, Halter S, Haschimi B, Alt A, Rentsch D, Schmidt B, Thoma V, Vogt S, Auwärter V (2019). "Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE". Forensic Toxicology. 38 (2): 314–326. doi:10.1007/s11419-019-00514-w. S2CID 209449526.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.